[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525334":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":10,"locations":28,"responsibleParty":64,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":10,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"Kidney sparing surgery+Postoperative radiotheray cohort",null,[12],"Radiation: Kidney sparing surgery+Postoperative radiotheray",{"label":14,"type":10,"description":15,"interventionNames":16},"Radical surgery cohort","Preoperative CT\u002FMRI, chest CT and other examinations are performed to determine the stage of the patient's disease. The surgical plan is the same as the current conventional treatment. After surgery, there is no restriction on the use of postoperative adjuvant chemotherapy or postoperative adjuvant radiotherapy according to the patient's pathological stage and the patient's wish.",[17],"Procedure: Radical surgery",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"PROCEDURE","Radical surgery","Radical nephroureterectomy",[14],{"type":25,"name":26,"description":26,"armGroupLabels":27,"otherNames":10},"RADIATION","Kidney sparing surgery+Postoperative radiotheray",[9],[29,51],{"facility":30,"status":31,"city":32,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Departmeng of Urology, Peking University First Hospital","RECRUITING","Beijing","China","CN",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42,47],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Xuesong Li, M.D.","CONTACT","+86-15801399116","pineneedle@sina.com",{"name":48,"role":44,"phone":49,"phoneExt":10,"email":50},"Chunru Xu, M.D.","+86-17812172086","xcrbdyy@126.com",{"facility":52,"status":31,"city":32,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"Department of Radiotherapy Oncology, Peking University First Hospital",{"type":36,"coordinates":54},[38,39],{"lat":39,"lon":38},[57,60],{"name":58,"role":44,"phone":10,"phoneExt":10,"email":59},"Xianshu Gao, M.D.","doctorgaoxs@126.com",{"name":61,"role":44,"phone":62,"phoneExt":10,"email":63},"Xiaoying Li, M.D.","+86-13716109164","13716109164@139.com",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Xuesong Li","Department of Urology","100525334","combined-postoperative-radiotherapy-with-kidney-sparing-surgery-for-locally-advanced-high-risk-ureteral-cancer-100525334",false,"NCT06120387","Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer","Inclusion Criteria:\n\n\\- 1) Ureteral cancer patients with high-risk factors (high-risk factors define multifocal; G3; T2-4); surgery may be performed with patients undergoing partial terminal ureteral resection or radical nephroureterectomy 2)Age ≥18 years; 3)Completion of abdominopelvic CT 4 weeks before enrollment to exclude distant metastasis and regional lymph node metastasis.\n\n4\\) Patients did not have other malignant neoplastic diseases in the last 5 years except for non-melanoma of the skin and ductal carcinoma in situ of the breast; Willing to participate in perfecting the necessary examinations and follow-up for the sake of the study, and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* 1\\) Distant metastasis or retroperitoneal lymph node metastasis (N+) had been detected at the time of surgery; R2 resection patients; history of bladder cancer; 2) History of pelvic and abdominal radiotherapy; history of inflammatory bowel disease; history of systemic chemotherapy; 3) Pregnant women or breastfeeding women; or women of childbearing potential who are not practicing reliable contraception; (4) The presence of active infections in those with pre-existing or coexisting bleeding disorders 5) clinically significant cardiac disease (e.g., hypertension controlled with medications, unstable angina, New York Heart Association (NYHA) class ≥II congestive heart failure, unstable symptomatic arrhythmias, or class ≥II peripheral vascular disease); 6) Psychological, family, and social factors leading to lack of informed consent.","ALL","18 Years",{"count":77,"type":78},90,"ESTIMATED","OBSERVATIONAL","In this study, we propose to conduct an ambispective study to analyze the safety of preserved renal unit surgery combined with postoperative adjuvant radiotherapy in patients with limited stage ureteral cancer with high risk factors, and the efficacy analysis compared with traditional radical surgery. It is hoped that a treatment method that preserves patients' renal function to improve the tolerance of subsequent drug therapy without decreasing the effect of tumor treatment can be achieved in patients with high-risk factors.",[82,83],"Locally Advanced","Urothelial Carcinoma Ureter",[85,86,87,88,89],"upper tract urothelial carcinoma","Radiotherapy","Kidney sparing surgery","Locally advanced","Ambispective cohort","2023-11-02",{"date":92,"type":93},"2023-11-07","ACTUAL",{"date":95,"type":78},"2023-11-10",{"date":97,"type":78},"2028-11-09",{"name":66,"class":6},2]